CMV Therapeutic Vaccine for the Treatment of Glioblastoma

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$246,026.00
Award Year:
2012
Program:
STTR
Phase:
Phase I
Contract:
1R41CA153845-01A1
Award Id:
n/a
Agency Tracking Number:
R41CA153845
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA10-051
Small Business Information
3 SEDGEWOOD RD, CHAPEL HILL, NC, 27514-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
831314344
Principal Investigator:
DUANE MITCHELL
(919) 684-1951
d.mitchell@duke.edu
Business Contact:
JAMES SHELDON
(919) 929-3688
jes10@duke.edu
Research Institute:
DUKE UNIVERSITY

DUKE UNIVERSITY
2200 W. Main St., Suite 820
DURHAM, NC, 27705-
() -
Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): Recently, temozolomide (TMZ), a myelosuppressive alkylating chemotherapy, has shown a benefit in patients with glioblastoma multiformes (GBM), but median survival is still less than 15 months. Moreover, these conventional chemotherapies lack specificity and result in incapacitating damage to surrounding normal brain and systemic tissues. Immunotherapy may provide an opportunity to eliminate altered neoplastic cells without adding additional toxicity to multi-modality therapy, but the lymphopenia induced by cycles of adjuvant TMZ, now the standard-of-care in patients with GBM, would be predicted to curtail the induction of productive immune responses. However, when given to patients with newly diagnosed glioblastoma multiforme during the recovery from TMZ-induced lymphopenia, the investigators demonstrated that a vaccine targeting a EGFRvIII mutation on GBM induced strong immunologic responses in all vaccinated patients that were accompanied by complete radiographic responses in patients with residual disease and prolonged survival compared to matched historical controls. However, the EGFRvIII mutation is expressed in only about a third of GBMs, limiting the number of patients who may benefit from this therapy and highlighting the need to target more ubiquitously expressed antigens. The recent discovery that greater than 90% of GBMs are associated with tumor-restricted reactivation of human cytomegalovirus (CMV) provides an opportunity to leverage the well characterized viralantigens of CMV as tumor-specific targets. Following a developmental pathway used successfully to advance EGFRvIII specific vaccines to large scale efficacy trials and commercialization, the investigators propose to evaluate the preclinical and clinical advancement of peptide vaccines targeting the immunodominant antigens of CMV. The objectives of this phase I STTR proposal are to finalize the composition of a multi-component peptide vaccine targeting CMV antigens through investigation of the impact of peptide length, hapten conjugation, and the inclusion of class II-restricted helper T cell epitopes on immunologic responses in HLA transgenic mice, and to determine the impact of vaccine dose and timing with respect to administration of TMZ in order to define variables worthy of investigation within the context of early phase clinical trials. PUBLIC HEALTH RELEVANCE: The significance of this research is that it may advance a new therapy for malignant brain tumors as well as provide a strategy for treatment that can be applied to many other cancers. Improved therapy for cancer has significant potential to improve public health and quality of life for patients affected by malignant disease.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government